Earnings revisions for multiple stocks, including Nxera Pharma, were reported after the close. The main revisions concerned operating profit and ordinary profit, with many stocks showing notable upward revisions in percentage terms.
The list of earnings revisions announced after the close includes many stocks, led by Nxera Pharma, as well as Fuso Pharmaceutical, Morishita Jintan and Shigematsu Works. Revisions on a consolidated basis are prioritised, with the fiscal year-end and revised items shown together.
Nxera Pharma's operating profit change rate from the previous figure to the current figure is 2143%, and its fiscal year-end is December, with operating profit as the revised item. Fuso Pharmaceutical's interim ordinary profit was revised up 133%, Morishita Jintan's interim operating profit 88%, and Shigematsu Works' net profit 74%.
Tadano's net profit was revised up 43%, AREHD's ordinary profit 28%, and Astellas Pharma's ordinary profit was revised by 17%. Revisions to interim and final profit items were also seen at multiple other stocks, with upward revisions standing out overall.